Organ-wide telomeric status in diseased and disease-free prostatic tissues

Prostate

Volumn 70, Issue 13, 2010, Pages 1471-1479

  Heaphy, Christopher M ^a,c   Fleet, Trisha M ^a   Treat, Eric G ^a,d   Lee, Sang Joon ^a   Smith, Anthony Y ^a   Davis, Michael S ^a   Griffith, Jeffrey K ^a,b   Fischer, Edgar G ^a   Bisoffi, Marco ^a,b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Benign prostatic hyperplasia; Field cancerization; Prostate cancer; Telomere alterations

Indexed keywords

ADULT; AGED; ARTICLE; ASSAY; CANCER THERAPY; DISEASE FREE INTERVAL; DNA CONTENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SLOT BLOT HYBRIDIZATION; TELOMERE; TITRIMETRY; ADENOCARCINOMA; ANALYSIS OF VARIANCE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TELOMERE;

EID: 77956627409     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21182     Document Type: Article

References (34)

1. De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, Nelson WG,. Human prostate cancer precursors and pathobiology. Urology 2003; 62 (5 Suppl 1): 55 -62.
2. Joshua AM, Evans A, Van der Kwast T, Zielenska M, Meeker AK, Chinnaiyan A, Squire JA,. Prostatic preneoplasia and beyond. Biochim Biophys Acta 2008; 1785 (2): 156 -181.
3. Dong JT,. Prevalent mutations in prostate cancer. J Cell Biochem 2006; 97 (3): 433 -447.
4. Feldser DM, Hackett JA, Greider CW,. Telomere dysfunction and the initiation of genome instability. Nat Rev Cancer 2003; 3 (8): 623 -627.
5. Gisselsson D, Jonson T, Petersen A, Strombeck B, Dal Cin P, Hoglund M, Mitelman F, Mertens F, Mandahl N,. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc Natl Acad Sci USA 2001; 98 (22): 12683 -12688.
6. Desmaze C, Soria JC, Freulet-Marriere MA, Mathieu N, Sabatier L,. Telomere-driven genomic instability in cancer cells. Cancer Lett 2003; 194 (2): 173 -182.
7. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, Meyne J, Ratliff RL, Wu JR,. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA 1988; 85 (18): 6622 -6626.
8. Maser RS, DePinho RA,. Telomeres and the DNA damage response: Why the fox is guarding the henhouse. DNA Repair (Amst) 2004; 3 (8-9): 979 -988.
9. Olovnikov AM,. Principle of marginotomy in template synthesis of polynucleotides. Dokl Akad Nauk SSSR 1971; 201 (6): 1496 -1499.
10. Smogorzewska A, van Steensel B, Bianchi A, Oelmann S, Schaefer MR, Schnapp G, de Lange T,. Control of human telomere length by TRF1 and TRF2. Mol Cell Biol 2000; 20 (5): 1659 -1668.
11. Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar AF, Hiyama K, Piatyszek MA, Shay JW,. Telomerase activity in human breast tumors. J Natl Cancer Inst 1996; 88 (2): 116 -122.
12. Lin Y, Miyamoto H, Fujinami K, Uemura H, Hosaka M, Iwasaki Y, Kubota Y,. Telomerase activity in human bladder cancer. Clin Cancer Res 1996; 2 (6): 929 -932.
13. Meeker AK,. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. Urol Oncol 2006; 24 (2): 122 -130.
14. Koeneman KS, Pan CX, Jin JK, Pyle JM III, Flanigan RC, Shankey TV, Diaz MO,. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). J Urol 1998; 160 (4): 1533 -1539.
15. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS,. Telomerase activity: A prevalent marker of malignant human prostate tissue. Cancer Res 1996; 56 (1): 218 -222.
16. Bisoffi M, Heaphy CM, Griffith JK,. Telomeres: Prognostic markers for solid tumors. Int J Cancer 2006; 119 (10): 2255 -2260.
17. Fordyce CA, Heaphy CM, Joste NE, Smith AY, Hunt WC, Griffith JK,. Association between cancer-free survival and telomere DNA content in prostate tumors. J Urol 2005; 173 (2): 610 -614.
18. Donaldson L, Fordyce C, Gilliland F, Smith A, Feddersen R, Joste N, Moyzis R, Griffith J,. Association between outcome and telomere DNA content in prostate cancer. J Urol 1999; 162 (5): 1788 -1792.
19. Fordyce CA, Heaphy CM, Griffith JK,. Chemiluminescent measurement of telomere DNA content in biopsies. Biotechniques 2002; 33 (1): 144 -146, 148.
20. Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, Cheng L,. Independent origin of multiple foci of prostatic intraepithelial neoplasia: Comparison with matched foci of prostate carcinoma. Cancer 1998; 83 (9): 1995 -2002.
21. Joshua AM, Vukovic B, Braude I, Hussein S, Zielenska M, Srigley J, Evans A, Squire JA,. Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer. Neoplasia 2007; 9 (1): 81 -89.
22. Meeker AK, Gage WR, Hicks JL, Simon I, Coffman JR, Platz EA, March GE, De Marzo AM,. Telomere length assessment in human archival tissues: Combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol 2002; 160 (4): 1259 -1268.
23. Vukovic B, Beheshti B, Park P, Lim G, Bayani J, Zielenska M, Squire JA,. Correlating breakage-fusion-bridge events with the overall chromosomal instability and in vitro karyotype evolution in prostate cancer. Cytogenet Genome Res 2007; 116 (1-2): 1 -11.
24. Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL,. Clinical implications and utility of field cancerization. Cancer Cell Int 2007; 7: 2.
25. Nonn L, Ananthanarayanan V, Gann PH,. Evidence for field cancerization of the prostate. Prostate 2009. 69: 1470 -1479.
26. Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK, Bisoffi M,. Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. Int J Oncol 2009; 35: 537 -546.
27. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J,. The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 2004; 172 (4 Pt 1): 1297 -1301.
28. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR,. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998; 159 (4): 1247 -1250.
29. Stamey TA,. Making the most out of six systematic sextant biopsies. Urology 1995; 45 (1): 2 -12.
30. Treat EG, Heaphy CM, Massie LW, Bisoffi M, Smith AY, Davis MS, Griffith JK,. Telomere DNA content in prostate biopsies predicts early rise in prostate-specific antigen after radical prostatectomy for prostate cancer. Urology 2009. 75: 724 -729.
31. Qian J, Wollan P, Bostwick DG,. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol 1997; 28 (2): 143 -148.
32. Wise AM, Stamey TA, McNeal JE, Clayton JL,. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002; 60 (2): 264 -269.
33. Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L,. Focal therapy for localized prostate cancer: A critical appraisal of rationale and modalities. J Urol 2007; 178 (6): 2260 -2267.
34. Fradet Y,. Biomarkers in prostate cancer diagnosis and prognosis: Beyond prostate-specific antigen. Curr Opin Urol 2009; 19 (3): 243 -246.